1. Home
  2. LAC vs VIR Comparison

LAC vs VIR Comparison

Compare LAC & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lithium Americas Corp.

LAC

Lithium Americas Corp.

HOLD

Current Price

$4.50

Market Cap

1.4B

ML Signal

HOLD

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

HOLD

Current Price

$9.47

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAC
VIR
Founded
2023
2016
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
2023
2019

Fundamental Metrics

Financial Performance
Metric
LAC
VIR
Price
$4.50
$9.47
Analyst Decision
Hold
Strong Buy
Analyst Count
6
8
Target Price
$6.17
$19.63
AVG Volume (30 Days)
6.2M
4.3M
Earning Date
01-01-0001
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
17.49
EPS
N/A
N/A
Revenue
N/A
$68,556,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$925.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.31
$4.16
52 Week High
$10.52
$10.91

Technical Indicators

Market Signals
Indicator
LAC
VIR
Relative Strength Index (RSI) 42.33 57.65
Support Level $4.37 $4.64
Resistance Level $5.40 $10.91
Average True Range (ATR) 0.24 0.61
MACD -0.02 -0.05
Stochastic Oscillator 23.08 49.69

Price Performance

Historical Comparison
LAC
VIR

About LAC Lithium Americas Corp.

Lithium Americas is a pure-play lithium producer. Following a deal with the US government, the firm will own 59% of one resource, Thacker Pass, which is located in northwest Nevada, with automaker General Motors owning 36% and the US government owning 5%. Thacker Pass is under construction and expected to begin production in 2028. Thacker Pass is one of the largest known lithium resources in the world. The project would be the first clay-based asset to enter production, and we estimate it will be in bottom half of the global cost curve. Management plans to develop Thacker Pass into a fully integrated lithium production site, with downstream refining capabilities on site, and will sell into the lithium chemical market.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Share on Social Networks: